Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review

After reviewing its portfolio to prioritize and assessing the respiratory syncytial virus (RSV) vaccine landscape, Janssen, a unit of Johnson & Johnson JNJ, will exit its investigational RSV adult vaccine program and discontinue its Phase 3 EVERGREEN study.
The Phase 3 study estimated to enroll over 27,000 participants.
Pfizer Inc PFE and GSK plc GSK have their RSV vaccine candidates under FDA review, with a decision expected in May to use their shots in adults 65 and older.
Pfizer also expects the FDA to decide by August whether the shot can be used in infants and pregnant women.
The RSV vaccine market is estimated to be over $5 billion and could exceed $10 billion by 2030, Reuters reported, citing analysts.
Data from a Phase 2b CYPRESS trial showed that the vaccine generated 80% protection against lower respiratory infections in older adults. By then, it had already initiated the large Phase 3 trial.
The investigational RSV adult vaccine also demonstrated an efficacy of 70% against any symptomatic RSV-associated acute respiratory infection.
Price Action: JNJ shares are up 0.69% at $152.86 on the last check Wednesday.
Photo Via Company

Overview Rating:

Speculative

0100